All News

Cognitive and behavioral techniques can improve physical function and overall well-being in patients with long COVID.

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.

The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Stigma surrounding HIV can lead to barriers to health care, including refusal to get care, that could help individuals who are living with the condition.

The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty among MS patients is linked to a host of complications.

In 2024, the most-read articles published in our flagship peer-reviewed journal, The American Journal of Managed Care® (AJMC®), touched on disease burden, policy consequences, and more.

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal (IVS) flattening in these patients.

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research.

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.

Compared with originator bevacizumab, the biosimilar version of bevacizumab had equal efficacy when used to treat metastatic colorectal cancer.

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

The health care provisions include key reforms targeting pharmacy benefit managers, extensions of Medicare telehealth flexibilities, and measures aimed at combating the opioid crisis and preparing for future pandemics.

Obesity, overweight, and hypertension could also affect the risk of retinopathy if not managed in patients.

Understanding postural orthostatic tachycardia syndrome is important in order to improve prevention and outcomes.

Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of vaccines, and the unmet potential of pegylated interferons.

Throughout 2024, the Center on Health Equity & Access explored critical gaps in health care access and innovative efforts to address them.

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.

Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).

Study identifies underutilization of testing, with disparities by race and sex.

Adolescent substance use remains at record lows in 2024, extending declines first observed during the COVID-19 pandemic.

Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.

Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.

Ellen Francis, PhD, discusses the benefits, challenges, and future implications of implementing earlier diabetes screening for pregnant women.